Rationalization of risk factors for venous thromboembolism in medical in-patients: a prospective study

Citation
P. Pottier et al., Rationalization of risk factors for venous thromboembolism in medical in-patients: a prospective study, J MAL VASC, 25(4), 2000, pp. 241-249
Citations number
25
Categorie Soggetti
Cardiovascular & Respiratory Systems
Journal title
JOURNAL DES MALADIES VASCULAIRES
ISSN journal
03980499 → ACNP
Volume
25
Issue
4
Year of publication
2000
Pages
241 - 249
Database
ISI
SICI code
0398-0499(200010)25:4<241:RORFFV>2.0.ZU;2-4
Abstract
Background: In terms of preventive management of venous thromboembolism in medical inpatients, very large differences may be observed. Rationalization of behaviour requires the evaluation of simple and logical parameters, whi ch takes into account both patient safety and economic considerations. Aim: The aim of this study was to evaluate a preventive scheme including th e rationalization of the indications and the use of low molecular weight he parin. Methods:- experimental design: Epidemiologic investigation. setting and patients: Patients hospitalized in five medical departments in the Hospital Center of Nantes, France. intervention: The risk of venous thromboembolism was rated as high, interme diate and low. Patients with high or intermediate risk were eligible for pr evention therapy (table I). measures: The main criterion was the occurrence during hospital stay of dee p or superficial venous thrombosis of the lower limbs, pulmonary embolism, or unexplained sudden death. The screening was based on clinical features d ouble-checked by venous doppler ultrasonography of the lower limbs and/or v entilation perfusion lung scanning. Results: 24,497 patients were eligible (table II), 15% were considered at r isk and treated with Nadroparin, 6% had the same risk profile but were not treated and 14.7% had low risk and no prevention. No bleeding event was rep orted. The incidence of Venous thromboembolism was 0.75%, 1.7% and 0.14% re spectively (p <0.01) (table III). This efficacy does not appear to depend o n body weight or the existence of multiple risk factors observed (table IV and V). Conclusions: This analysis of risk factors separates two populations with r ates of incidence dramatically and significantly different. The prevention of venous thromboembolism by fixed dose of low molecular weight heparin rem ains justified since it reduces the risk of venous thromboembolism by a fac tor of 2.5.